SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to a report of security flaws in a battlefield communications system, leading to a sharp intraday drop. While some investors are concerned about the implications of these vulnerabilities, others view the dip as a buying opportunity, citing the company's response that the issues have been addressed and the prototype nature of the system.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a mix of excitement and skepticism around its recent surge, with community members debating whether it's a legitimate rise or a potential bubble. The stock's connection to the quantum computing sector and AI, coupled with discussions about its valuation and revenue, are fueling the conversations. Some traders are pointing to potential short squeezes, while others are wary of a significant pullback.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid high trading volume and community excitement, with some investors anticipating significant catalysts in the near future, possibly driven by speculation around new partnerships. Community members are pointing to the high short interest, hinting at a potential squeeze, while also highlighting the company's potential for growth in the eVTOL sector.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

LKNCY is trending as investors celebrate the stock finally breaking the $40 mark, a level many have been watching for a long time, driven by expansion news. The community is expressing bullish sentiment, anticipating further growth and a potential Nasdaq relisting. Overall, the mood is optimistic as traders reflect on the company's journey and future potential.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the implications of its AI spending and recent moves into private debt markets, drawing comparisons to pre-2008 financial tactics. Community discussion revolves around the stock's volatility and whether its pullback represents a buying opportunity or reflects deeper concerns about AI investments. Some are pointing to potential data center deals as a possible catalyst.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience ($ANRO) is trending as investors react to news of $IMG pulling its S-1 filing, eliminating concerns about potential dilution. The community is also buzzing about ANRO's expansion into crypto AI, including a $55M Bitcoin deal and a $20M fund with iZUMi. Bullish sentiment seems to be building amidst discussions of potential breakouts and short squeezes.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

SCLX is trending due to a sharp decline in its stock price, sparking community concern and speculation about the reasons behind it, including the potential impact of the DVLT deal and the company's leadership. Some investors are questioning the company's direction, while others are anticipating a potential short squeeze or positive news to reverse the current trend. Discussions also involve the possibility of a strategic play related to Semnur and its valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble ($RUM) is trending due to its strategic partnership with Perplexity AI, sparking discussions about enhanced content discovery and potential synergies within the AI space. The community is actively debating the impact of this partnership, especially given Rumble's existing ties to crypto through Tether and its potential to become a major cloud provider. High short interest is adding fuel to the fire, with many anticipating a significant short squeeze.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending with significant volume, fueled by community excitement and talk of a potential surge to new highs. Investors are actively discussing the company's potential to reach mid-cap status and the anticipation of news in October, while some reference a past short report as a catalyst for the stock's recent momentum. Discussion also includes comparisons to other robotics companies and speculation around the impact of robotics on the future.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

TDOC is trending as community members discuss its potential for a short squeeze, citing high short interest and upcoming catalysts. Bullish sentiment is fueled by mentions of technical indicators, such as breaking above key moving averages, and speculation around potential AI integration and partnerships. Some investors express frustration with the stock's historical performance and management, while others remain optimistic about its long-term growth potential in the telehealth sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a href="https://stocktwits.com/symbol/RGC">Regencell Bioscience Holdings Ltd</a>. (RGC), a Hong Kong-based nano-cap biotech firm, has emerged as one of the most explosive stocks of 2025, skyrocketing 14,486% year-to-date.The staggering rally has captivated retail traders and propelled the stock into the top trending ranks of healthcare chatter on Stocktwits.Over the past three months, message volume surrounding RGC has surged by 17,600% on Stocktwits, while its follower count has jumped 156%, reflecting some of the most intense engagement seen among small-cap health care stocks.Sentiment has mostly remained bullish over the same period, though cracks of doubt have&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">emerged</a> as traders digest the stock’s rise despite no formal news or clear catalysts.<figure class="image"><img style="aspect-ratio:1322/1354;" src="https://news.stocktwits-cdn.com/RGC_YTD_chart_with_sentiment_meter_and_message_volume_as_of_May_29_png_6a489def8e.webp" alt="RGC YTD chart with sentiment meter and message volume as of May 29.png" width="1322" height="1354"><figcaption>RGC YTD chart with sentiment meter and message volume as of May 29. | source: Stocktwits</figcaption></figure>Many retail investors remain wary, with some warning of a looming correction."$RGC one of these days this dumps 99% in [a] single trading session," said one user.<stembedurl>https://stocktwits.com/ItSaulGoodMaan/message/616270456</stembedurl>"$RGC this went up 20,000 % in 3 months, if they didn’t just cure cancer, then this is a scam," said another.<stembedurl>https://stocktwits.com/Lard_ass_piggy/message/616269720</stembedurl>Hong Kong-based Regencell focuses on traditional Chinese medicine (TCM), developing formulas aimed at treating ADHD and autism spectrum disorder (ASD).Despite its mission, the company has yet to commercialize any treatments, apply for regulatory approvals, or secure patents.&nbsp;In its most recent annual filing in October, the firm disclosed net losses of $4.36 million for fiscal 2024 and noted it may “never be profitable.”Insider activity appears to be fueling much of the move. According to media reports, insiders control 81% of the float, limiting public liquidity and potentially amplifying volatility.As of June 30, 2024, Regencell reported $8 million in cash and short-term investments, which it believed was enough to cover expenses for at least the following 12 months. However, it said it will likely need “substantial additional financing” to continue operations.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Biotech Stock's Mind-Blowing 14,400% YTD Rally Draws Frenzied Retail Interest

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.

Equity

Many retail investors remain wary, with some warning of a looming correction in the absence of formal news or clear catalysts.


Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

Regencell Bioscience Holdings Ltd. shares have been on a tear recently, more than tripling in value even before the first quarter of 2025 has ended. Retail traders, however, are not overly bullish about this stock.Hong Kong-based Regencell focuses on the research, development, and commercialization of traditional Chinese medicine, targeting neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD).According to several media&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://finance.yahoo.com/news/insiders-regencell-bioscience-holdings-limited-120457560.html">reports</a>, the recent rally has been driven mainly by buying from insiders, who own 81% of the company.The stock’s&nbsp;surge also comes amid a broader rally in Chinese stocks, driven by hopes of economic stimulus from Xi Jinping’s government.Koyfin data shows that only three institutional investors have a combined stake of a little over $156,000 in the company.A Stocktwits poll gauging retail sentiment on Regencell showed that 52% of nearly 1,000 respondents opted to stay away from the stock as it was "too risky for me," while 31% suggested they were buying it now.&nbsp;Another 12% said they were selling and taking profits, while 5% claimed to have "caught the move early."<figure class="image"><img style="aspect-ratio:1316/654;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/RGC_Stocktwits_poll_results_png_e989704d45.webp" alt="RGC Stocktwits poll results .png" width="1316" height="654"><figcaption>RGC Stocktwits poll results</figcaption></figure>Over the past three months, Regencell's following on Stocktwits has grown by 48% while message volume has soared by 30,000%.One bullish user claimed they bought Regencell stock when it was less than half its last close.<stembedurl>https://stocktwits.com/CryptoSenderX/message/607994621</stembedurl>However, a skeptic argued that RGC actually moved up "on no news. I'm shorting and waiting for the rug pull."<stembedurl>https://stocktwits.com/SmoothD/message/608057630</stembedurl>Regencell has not generated revenue or a profit ever since it went public on the Nasdaq in July 2021.&nbsp;It has a low float of about 802,000 shares, making it a highly volatile stock.One Stocktwits user expressed strong skepticism, saying, "This reeks of a scam so bad. Hong Kong biotech with 12 full-time employees. Chinese medicine ancient herbs for ADHD. This will collapse."<stembedurl>https://stocktwits.com/jimmieB/message/608370796</stembedurl>According to Koyfin, no analysts currently cover the stock on Wall Street. The stock ended Monday 46% higher and jumped another 42% in after-hours trading.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regencell Bioscience Stock Is Up Over 260% This Year — Are Retail Traders Riding The Wave Or Watching From The Sidelines?

The Hong Kong-based company focuses on researching, developing, and commercializing traditional Chinese medicine, targeting neurocognitive disorders and degeneration.

12 titoli sanitari in movimento, sessione regolare del 22/03/2024

Titoli in rialzo
Il titolo IMAC Hldgs (NASDAQ:BACK) salito del 93,02% a 2,49 dollari durante la sessione regolare di venerd .
Il titolo Regencell Bioscience (NASDAQ:RGC) ha osservato un incremento...

12 acciones de salud en movimiento en la sesi n intrad a del 11/03/2024

Acciones al alza
Regencell Bioscience (NASDAQ:RGC) experimentaron un repunte del 130,88% para establecerse en los 10,39 d lares durante la sesi n del regular del lunes.
TC BioPharm (Holdings...

Regencell Bioscience Holdings Ltd trading resumes

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Regencell Bioscience Holdings Ltd trading halted, volatility trading pause

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. It seeks the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

RGC
Regencell Bioscience Holdings Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RGC News

RGC Regencell Bioscience Holdings Ltd